Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRN NASDAQ:BCYC NASDAQ:HRTX NASDAQ:IRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$14.52-1.2%$15.06$12.96▼$20.90$304.48M0.880,142 shs33,614 shsBCYCBicycle Therapeutics$4.24-2.5%$4.35$3.92▼$9.18$296.13M1.55439,512 shs148,794 shsHRTXHeron Therapeutics$0.42+1.0%$0.64$0.38▼$2.14$79.88M1.652.53 million shs2.25 million shsIRDOpus Genetics$3.62-5.1%$4.28$1.04▼$5.81$298.49M0.55943,919 shs573,555 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin-1.21%-6.55%-3.54%+1.03%-13.17%BCYCBicycle Therapeutics-1.36%0.00%+7.41%-14.03%-45.63%HRTXHeron Therapeutics+0.60%-3.92%+4.20%-55.51%-80.88%IRDOpus Genetics-2.81%-6.39%-5.69%-31.35%+237.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$14.52-1.2%$15.06$12.96▼$20.90$304.48M0.880,142 shs33,614 shsBCYCBicycle Therapeutics$4.24-2.5%$4.35$3.92▼$9.18$296.13M1.55439,512 shs148,794 shsHRTXHeron Therapeutics$0.42+1.0%$0.64$0.38▼$2.14$79.88M1.652.53 million shs2.25 million shsIRDOpus Genetics$3.62-5.1%$4.28$1.04▼$5.81$298.49M0.55943,919 shs573,555 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin-1.21%-6.55%-3.54%+1.03%-13.17%BCYCBicycle Therapeutics-1.36%0.00%+7.41%-14.03%-45.63%HRTXHeron Therapeutics+0.60%-3.92%+4.20%-55.51%-80.88%IRDOpus Genetics-2.81%-6.39%-5.69%-31.35%+237.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 2.50Moderate BuyN/AN/ABCYCBicycle Therapeutics 2.44Hold$14.00230.03% UpsideHRTXHeron Therapeutics 2.00Hold$2.50493.82% UpsideIRDOpus Genetics 2.88Moderate Buy$10.77197.90% UpsideCurrent Analyst Ratings BreakdownLatest HRTX, IRD, AMRN, and BCYC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2026BCYCBicycle Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/6/2026IRDOpus Genetics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.007/6/2026IRDOpus Genetics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.006/23/2026IRDOpus Genetics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.006/23/2026IRDOpus Genetics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageModerate Buy$10.006/18/2026IRDOpus Genetics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $13.006/17/2026IRDOpus Genetics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/17/2026IRDOpus Genetics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.006/16/2026AMRNAmarin Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/16/2026IRDOpus Genetics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.006/15/2026IRDOpus Genetics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$11.00(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$213.65M1.43$0.35 per share41.22$22.07 per share0.66BCYCBicycle Therapeutics$72.86M4.06N/AN/A$8.79 per share0.48HRTXHeron Therapeutics$154.90M0.51N/AN/A$0.07 per share6.01IRDOpus Genetics$14.20M21.02N/AN/A$0.22 per share16.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$38.80M-$0.65N/AN/AN/A-15.51%-2.99%-2.07%7/29/2026 (Estimated)BCYCBicycle Therapeutics-$218.96M-$3.15N/AN/AN/A-344.95%-35.74%-29.54%8/14/2026 (Estimated)HRTXHeron Therapeutics-$20.19M-$0.18N/AN/AN/A-20.53%-7,747.30%-8.94%8/14/2026 (Estimated)IRDOpus Genetics-$49.59M-$1.33N/AN/AN/A-892.36%-338.88%-191.21%8/12/2026 (Estimated)Latest HRTX, IRD, AMRN, and BCYC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2026Q2 2026AMRNAmarin-$0.01N/AN/AN/A$44.55 millionN/A5/12/2026Q1 2026IRDOpus Genetics-$0.16-$0.75-$0.59-$0.75$2.93 million$2.16 million5/11/2026Q1 2026HRTXHeron Therapeutics-$0.03-$0.04-$0.01-$0.04$36.72 million$34.71 million4/30/2026Q1 2026BCYCBicycle Therapeutics-$0.6209-$0.87-$0.2491-$0.87$7.50 million$0.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/ABCYCBicycle TherapeuticsN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.482.46BCYCBicycle TherapeuticsN/A12.6612.66HRTXHeron Therapeutics17.512.531.51IRDOpus GeneticsN/A7.137.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%BCYCBicycle Therapeutics86.15%HRTXHeron Therapeutics80.01%IRDOpus Genetics14.97%Insider OwnershipCompanyInsider OwnershipAMRNAmarin4.21%BCYCBicycle Therapeutics22.00%HRTXHeron Therapeutics6.10%IRDOpus Genetics11.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.97 million20.09 millionOptionableBCYCBicycle Therapeutics24069.81 million54.45 millionOptionableHRTXHeron Therapeutics300189.28 million177.73 millionOptionableIRDOpus Genetics1482.57 million72.91 millionN/AHRTX, IRD, AMRN, and BCYC HeadlinesRecent News About These CompaniesCantor Fitzgerald Reaffirms Their Buy Rating on Opus Genetics (IRD)July 11 at 10:08 PM | theglobeandmail.comOpus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 ResultsJuly 9, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Opus Genetics (IRD) and Vertex Pharmaceuticals (VRTX)July 8, 2026 | theglobeandmail.comOpus Genetics' (IRD) "Buy" Rating Reaffirmed at BTIG ResearchJuly 7, 2026 | americanbankingnews.comOpus Genetics' (IRD) "Buy" Rating Reaffirmed at Chardan CapitalJuly 7, 2026 | americanbankingnews.comOpus Genetics (NASDAQ:IRD) Receives "Buy" Rating from BTIG ResearchJuly 6, 2026 | marketbeat.comOpus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal DiseaseJuly 6, 2026 | globenewswire.comRBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked SetupJuly 5, 2026 | finance.yahoo.com5 Overlooked Penny Stocks to Buy Right NowJuly 4, 2026 | insidermonkey.comOpus Genetics Advances New Gene Therapy Trial for Rare Childhood BlindnessJuly 2, 2026 | tipranks.comJonesTrading Sticks to Their Buy Rating for Opus Genetics (IRD)June 27, 2026 | theglobeandmail.comOpus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® IndexesJune 26, 2026 | globenewswire.comOppenheimer Sticks to Their Buy Rating for Opus Genetics (IRD)June 19, 2026 | theglobeandmail.comOpus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases TranscriptJune 17, 2026 | seekingalpha.comOpus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal DiseasesJune 16, 2026 | globenewswire.comGuggenheim Initiates Coverage Of Opus Genetics (IRD) With “Buy” Rating And $16 Price TargetJune 10, 2026 | finance.yahoo.comOpus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease ExpertsJune 2, 2026 | globenewswire.comOpus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 28, 2026 | globenewswire.comOpus Genetics to Present at the 2026 Jefferies Global Healthcare ConferenceMay 27, 2026 | globenewswire.comLeerink Partners initiates coverage of Opus Genetics (IRD) with outperform recommendationMay 22, 2026 | msn.comOpus Genetics (NASDAQ:IRD) Director Sells $7,395,000.00 in StockMay 21, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAST SpaceMobile Announces Launch Date for Its Next 3 BlueBird SatellitesBy Jessica Mitacek | June 16, 2026AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?By Jessica Mitacek | June 26, 2026AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in FocusBy Jessica Mitacek | July 3, 2026Rocket Lab Defies Gravity With $8B BuyoutBy Jeffrey Neal Johnson | June 30, 2026Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponBy Jeffrey Neal Johnson | July 2, 2026HRTX, IRD, AMRN, and BCYC Company DescriptionsAmarin NASDAQ:AMRN$14.52 -0.18 (-1.22%) As of 03:06 PM Eastern This is a fair market value price provided by Massive. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Bicycle Therapeutics NASDAQ:BCYC$4.24 -0.11 (-2.48%) As of 03:05 PM Eastern This is a fair market value price provided by Massive. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Heron Therapeutics NASDAQ:HRTX$0.42 +0.00 (+0.98%) As of 03:05 PM Eastern This is a fair market value price provided by Massive. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Opus Genetics NASDAQ:IRD$3.62 -0.20 (-5.12%) As of 03:06 PM Eastern This is a fair market value price provided by Massive. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet 3 Overlooked Energy ETFs Delivering Strong Returns and Income 3 Space Stocks That Could Outshine SpaceX After Its IPO 3 Energy Stocks Racing to Fix AI's Power Problem JPMorgan’s Q2 Strength Gives the Stock Rally New Support No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
